> ## Content Index > Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt > Use this file to discover other available public pages before exploring further. # Janssen COVID-19 vaccine - URL: https://www.whiteroseintelligence.com/janssen-covid-19-vaccine/ - Published: 1999-01-02T18:42:00.000Z - Updated: 2026-02-20T04:33:20.000Z - Author: Liam Sturgess - Tags: Profiles, #docs, #pharmaproduct, COVID-19, Product The **Janssen COVID-19 vaccine** is a genetic [COVID-19 vaccine](https://www.whiteroseintelligence.com/COVID-19-vaccine) product developed by [Janssen](https://www.whiteroseintelligence.com/Janssen), a subsidiary of [Johnson & Johnson](https://www.whiteroseintelligence.com/Johnson-&-Johnson). It is also known in various contexts as **Ad26.COV2.S**, the **Johnson & Johnson COVID-19 vaccine**, and by its brand name, **Jcovden**. ## History On April 23, 2020, [Emergent BioSolutions](https://www.whiteroseintelligence.com/Emergent-BioSolutions) announced it had entered a $135 million agreement with Johnson & Johnson to "provide contract development and manufacturing services" for the Janssen COVID-19 vaccine.[\[1\]](#fn1) On July 6, 2020, Emergent BioSolutions announced an additional five-year contract with Johnson & Johnson, building on the prior agreement.[\[2\]](#fn2) After the first two years, Emergent would "provide a flexible capacity deployment model to support additional drug substance batches annually."[\[3\]](#fn3) ### Authorization [Health Canada](https://www.whiteroseintelligence.com/Health-Canada) authorized the vaccine on March 5, 2021 under interim order. The decision was made based on an interim analysis of Janssen's clinical trial data collected up to January 22, 2021.[\[4\]](#fn4) On November 22, 2021, Health Canada transitioned the regulatory status of the vaccine from being authorized under the interim order to being authorized under Division 8 of the Food and Drug Regulations.[\[5\]](#fn5) In late 2021, Johnson & Johnson neared completion of a deal to have [Aspen Pharmacare](https://www.whiteroseintelligence.com/Aspen-Pharmacare) manufacture the Janssen COVID-19 vaccine product in Africa.[\[6\]](#fn6) ### End of the pandemic On May 7, 2023, "all remaining [U.S. government](https://www.whiteroseintelligence.com/United-States-Federal-Government) stock" of the Janssen product was officially declared as expired by the [Centers for Disease Control and Prevention](https://www.whiteroseintelligence.com/Centers-for-Disease-Control-and-Prevention) (CDC).[\[7\]](#fn7) As of May 10, 2023, the product was "no longer available in the United States."[\[8\]](#fn8) ## Documents - February 16, 2023: [Product monograph](https://web.archive.org/web/20230610033309/https://covid-vaccine.canada.ca/info/pdf/janssen-covid-19-vaccine-pm-en.pdf) ### National contracts **South Africa** Between Pfizer and the National Department of Health of South Africa. - November 19, 2020: [Term Sheet (internal draft)](https://web.archive.org/web/20231025172635/https://healthjusticeinitiative.org.za/wp-content/uploads/2023/09/OCRJanssen-3-no-sig.pdf) - February 26, 2021: [Advance Purchase Agreement](https://web.archive.org/web/20231025172144/https://healthjusticeinitiative.org.za/wp-content/uploads/2023/09/OCRJanssen-1%5FRedacted.pdf) - April 2021: [Advance Purchase Agreement (Additional Doses)](https://web.archive.org/web/20230930130526/https://healthjusticeinitiative.org.za/wp-content/uploads/2023/09/OCRJanssen-2%5FRedacted.pdf) ## Clinical trials - A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE) ## External links - [Wikipedia](https://en.wikipedia.org/wiki/Janssen%5FCOVID-19%5Fvaccine) - [Wikispooks](https://wikispooks.com/wiki/Johnson%5F%26%5FJohnson%5FCOVID-19%5Fvaccine) --- 1. Neri, M. B., & Burrows, R. G. (2020, April 23). *Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19.* Emergent BioSolutions. [http://archive.today/2023.06.14-015555/https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-be-us-manufacturing?field\_nir\_news\_date\_value\[min\]=](http://archive.today/2023.06.14-015555/https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-be-us-manufacturing?field%5Fnir%5Fnews%5Fdate%5Fvalue%5Bmin%5D=) [↩︎](#fnref1) 2. Knapp, A. (2021, March 1). *Little-Known Publicly Traded Company Given Massive Deal To Manufacture One-Shot Covid-19 Vaccine.* Forbes. [↩︎](#fnref2) 3. Neri, M. B., & Burrows, R. G. (2020, July 6). *Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate.* Emergent BioSolutions. [↩︎](#fnref3) 4. *Regulatory Decision Summary - Janssen COVID-19 Vaccine - Health Canada.* (2021, March 5). Government of Canada. [↩︎](#fnref4) 5. *Regulatory Decision Summary - Janssen COVID-19 Vaccine - Health Canada.* (2021, November 22). Government of Canada. [↩︎](#fnref5) 6. Jerving, S. (2021, December 6). *Aspen’s COVID-19 vaccine licensing deal a “game changer” for Africa.* Devex. [↩︎](#fnref6) 7. National Center for Immunization and Respiratory Diseases. (2023, May 10). *Johnson & Johnson’s Janssen COVID-19 Vaccine Information.* Centers for Disease Control and Prevention. [↩︎](#fnref7) 8. McPhillips, D. (2023, May 15). *J&J Covid-19 vaccine no longer available in the US.* CNN. [↩︎](#fnref8)